First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Authors: Rizwan Romee, Sarah Cooley, Melissa M. Berrien-Elliott, Peter Westervelt, Michael R. Verneris, John E. Wagner, Daniel J. Weisdorf, Bruce R. Blazar, Celalettin Üstün, Todd E. DeFor, Sithara Vivek, Lindsey Peck, John F. DiPersio, Amanda F. Cashen, Rachel L. Kyllo, Amy Musiek, András Schaffer, Milan J. Anadkat, Ilana S. Rosman, Daniel D. Miller, Jack O. Egan, Emily K. Jeng, Amy D. Rock, Hing C. Wong, Todd A. Fehniger, Jeffrey S. Miller - Blood 2018 cited by 407

T cell numbers and function. This immunostimulatory IL-15 superagonist warrants further investigation to augment antitumor immunity alone and combined with other immunotherapies. This trial was registered at www.clinicaltrials.gov as #NCT01885897.